Effect of oral tranexamic acid on erythema index in patients with melasma
- Resource Type
- Authors
- Michelle Rodrigues; Eldho Paul; Angelique Ross; Jennifer Nguyen; Celestine C Wong; Harini Rajgopal Bala
- Source
- Australasian Journal of Dermatology. 62:206-209
- Subject
- Adult
medicine.medical_specialty
Erythema
Melasma
Administration, Oral
Dermatology
Placebo
Severity of Illness Index
Melanosis
law.invention
030207 dermatology & venereal diseases
03 medical and health sciences
0302 clinical medicine
Randomized controlled trial
law
Humans
Medicine
In patient
Vascular proliferation
business.industry
Middle Aged
medicine.disease
Hyperpigmentation
Tranexamic Acid
030220 oncology & carcinogenesis
Dermatologic Agents
medicine.symptom
business
Tranexamic acid
medicine.drug
- Language
- ISSN
- 1440-0960
0004-8380
Melasma is a common disorder of hyperpigmentation that presents a therapeutic challenge for clinical dermatologists. The pathogenesis is complex, but previous studies have demonstrated vascular proliferation is a key factor in the development of the classic hyperpigmented patches. Studies have revealed reduction of erythema by oral tranexamic acid; however, there has been no direct comparison to placebo. This 24-week randomised placebo-controlled trial demonstrates oral tranexamic acid may improve erythema in melasma. This mechanism of action may be the reason for the success of tranexamic acid in complex and difficult to treat melasma.